SYRS
Syros Pharmaceuticals Inc (SYRS)
$4.51.81%▲
Market is closedMarket is closed – opens on 8 PM, 30 Jan 2023
– opens on 8 PM, 30 Jan 2023
Key Stats
$4.37
Day's Range
$4.59
$3.02
52-Week Range
$21.9
| Returns % | |
| 1 month return | 31.96% |
| 3 month return | 10.36% |
| 1 year return | 77.27% |
| 5 year return | 95.79% |
Analyst Recommendation
based on 12 analysts ratings
Buy
91%
Buy
8%
Hold
0%
Sell
Based on 12 Wall street analysts offering stock ratings for Syros Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 642.22%Current
$4.5
Target
$33.4
Recommendation Trend
Based on 12 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 11 | 11 | 11 |
| Hold | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 92.8M |
| Book Value | $6.39 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.55 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 33.4 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.58 |
| Enterprise Value | -105674093 |
| Enterprise Value/Revenue | 2.58 |
| Enterprise Value/Ebitda | 0.99 |
Technicals
| Beta | 1.44 |
| 50 Day MA | 3.85 |
| 200 Day MA | 6.89 |
Institutional Holdings
Artal Group S A
7.24%
Bain Capital Life Sciences Investors, LLC
5.35%
Flagship Ventures Management, Inc.
4.91%
Avidity Partners Management LP
4.45%
Ally Bridge Group (NY) LLC
4.29%
Adage Capital Partners Gp LLC
3.57%
Company Information
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
| Organization | Syros Pharmaceuticals Inc |
| Employees | 124 |
| CEO | Dr. Nancy A. Simonian M.D. |
| Industry | Health Technology |
Discover more
Frequently Asked Questions
What is Syros Pharmaceuticals Inc share price today?
Can Indians buy Syros Pharmaceuticals Inc shares?
How can I buy Syros Pharmaceuticals Inc shares from India?
Can Fractional shares of Syros Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Syros Pharmaceuticals Inc stocks?
What are today’s High and Low prices of Syros Pharmaceuticals Inc?
What are today’s traded volumes of Syros Pharmaceuticals Inc?
What is today’s market capitalisation of Syros Pharmaceuticals Inc?
What is the 52 Week High and Low Range of Syros Pharmaceuticals Inc?
How much percentage Syros Pharmaceuticals Inc is down from its 52 Week High?
How much percentage Syros Pharmaceuticals Inc is up from its 52 Week low?
What are the historical returns of Syros Pharmaceuticals Inc?
Who is the Chief Executive Officer (CEO) of Syros Pharmaceuticals Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*